|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Building and Maintaining a Multidisciplinary Team for Lysosomal Disorders
This CME/CE activity with Drs. Ozlem Goker-Aplan and Walla Al-Hertani describes the importance of a multidisciplinary team approach to managing lysosomal diseases, as well as some of the challenges involved in creating and maintaining that team.
At the end of this activity, participants should be able to:
- Describe the need for a team approach to care
- Describe best practices to build a multidisciplinary team for a new patient
- Describe best practices to maintain a multidisciplinary... |
|
|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
|
Acromegaly Research Highlights: ENDO 2023
This 30-minute CME-accredited program highlights the latest clinical research about acromegaly, a rare endocrine disorder. Common symptoms include subtle skeletal overgrowth; soft tissue swelling (tongue, heart, kidney, colon, and vocal cords); unusually prominent forehead and heavy brow ridge; protruding lower jaw; overbite; skin thickening; increased shoe and ring size; hypertension; increased perspiration; headaches; paresthesia; and sexual dysfunction.
There are several orphan drugs app... |
|
|
Managing Cardiomyopathies in Lysosomal Disorders
This CME/CE activity describes the pathophysiologies and management options for lysosomal disease patients with cardiomyopathies.
At the end of this activity, participants should be able to:
- Describe the role of the cardiologist in the team approach to care
- Describe best practices to monitor cardiac symptoms in lysosomal disorders
- Describe best practices to treat cardiac symptoms in lysosomal disorders |
|
|
Cushing’s Disease Research Highlights: ENDO 2023
This 30-minute CME program highlights the latest clinical research about Cushing’s disease.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor that leads to excessive levels of cortisol.
This CME program, hosted by Lisa Machtigall, MD, Clinical Director, Neuroendocrine & Pituitary Tumor Clinical Center at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School, provides an overview of the latest cli... |
|
|
New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)
This 30-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine.
This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management... |
|
|
Myasthenia Gravis and the Complement System
This 45-minute CME-accredited program, hosted by James F Howard Jr, MD, Professor of Neurology, Medicine & Allied Health at The University of North Carolina at Chapel Hill, highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease.
After participating in the activity, learners should be better able to:
- Review the pathophysiology of MG.
- Describe the role of the complement system in MG.
- Descr... |
|
|
Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders
Ozlem Gore-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.
At the end of this activity, participants should be able to:
- Describe the most common LSDs that have pulmonary complications.
- Describe best practices to manage pulmonary symptoms in Pompe disease.
- Describe best practices to manage pulmonary symptoms in MPSs.
- Describe best practices to... |
|